Retatrutide 20mg
The Apex of Metabolic Research: The World’s First Triple-Receptor Agonist
Retatrutide (LY3437943) is the most mechanistically advanced synthetic peptide currently in the incretin research class. By simultaneously targeting the GLP-1, GIP, and glucagon receptors, it represents a massive leap forward from dual-agonist compounds, offering unprecedented synergistic effects for metabolic and obesity research.
Breakthrough Research Benefits:
- Unmatched Weight Reduction Models: Phase 2 data (NEJM, 2023) demonstrated dose-dependent body weight reductions of up to 24% over 24 weeks.
- Elevated Energy Expenditure: The addition of glucagon receptor activation drives hepatic fat oxidation and thermogenesis—a key differentiator from earlier compounds.
- Comprehensive Metabolic Repair: Shown to significantly improve fasting glucose, triglycerides, HbA1c, and insulin sensitivity in preclinical models.
Available Dosages:
- 20mg (RT20): The highest-load formulation available, designed for extended protocols and comparative dosing studies.
Storage & Handling:
- Lyophilised: Store at −20°C long-term (4°C acceptable for up to 4 weeks).
- Reconstitution: Use bacteriostatic water. Add solvent slowly along the vial wall and swirl gently (do not shake).
- Reconstituted: Store at 4°C, protect from light, avoid freeze-thaw cycling, and use within 28 days.
